Wedbush Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BTIG Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral
May 11, 2016 7:19 AM EDTBTIG downgraded EPIRUS Biopharmaceuticals (NASDAQ: EPRS) from Buy to Neutral. Yesterday the company announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases.
"Epirus announced management changes and a strategic change in direction yesterday,... More
EPIRUS Biopharma (EPRS) Will Reallocate Resources to Focus on BOW080, BOW070 Development
May 9, 2016 4:01 PM EDTEPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases. This includes reallocating the Companys resources to focus on the development of BOW080 (eculizumab; reference... More
